株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

寒冷凝集素症(CAD)- 市場洞察、疫学、市場予測

Cold Agglutinin Disease (CAD) - Market Insight, Epidemiology and Market Forecast - 2030

発行 DelveInsight Business Research LLP 商品コード 911509
出版日 ページ情報 英文 150 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.92円で換算しております。
寒冷凝集素症(CAD)- 市場洞察、疫学、市場予測 Cold Agglutinin Disease (CAD) - Market Insight, Epidemiology and Market Forecast - 2030
出版日: 2020年01月01日 ページ情報: 英文 150 Pages
概要

新興10カ国(トルコ、ロシア、サウジアラビア、アラブ首長国連邦、メキシコ、コロンビア、ブラジル、アルゼンチン、中国、台湾)の寒冷凝集素症(CAD)の2017年の有病数は2万9,077人、その市場規模は約2,680万米ドルと推計されています。

当レポートでは、新興10カ国(トルコ、ロシア、サウジアラビア、アラブ首長国連邦、メキシコ、コロンビア、ブラジル、アルゼンチン、中国、台湾)の寒冷凝集素症(CAD)市場を調査し、市場および疾病の概要、性別・タイプ・年齢・国別の疫学的予測、アンメットニーズ、新薬の概要、全体および各国の市場規模の推移と予測、市場の成長要因および障壁の分析などをまとめています。

目次

第1章 重要洞察

第2章 寒冷凝集素症(CAD)市場の概要

  • 分布状況(実績値)
  • 分布状況(予測値)

第3章 寒冷凝集素症(CAD):疾病背景と概要

  • イントロダクション
  • 兆候と症状
  • クローン性と組織病理学
  • 病因
  • 診断

第4章 疫学および患者人口:地域別

  • 主な調査結果

第5章 新興10カ国の疫学

  • 新興10カ国の寒冷凝集素症(CAD)有病数

第6章 寒冷凝集素症(CAD)の疫学

  • 仮定と根拠
  • アジア
    • 台湾
      • 有病数
      • 有病数:性別
      • 有病数:タイプ別
      • 有病数:年齢別
    • 中国
      • 有病数
      • 有病数:性別
      • 有病数:タイプ別
      • 有病数:年齢別
  • 中東
    • サウジアラビア
      • 有病数
      • 有病数:性別
      • 有病数:タイプ別
      • 有病数:年齢別
    • アラブ首長国連邦
      • 有病数
      • 有病数:性別
      • 有病数:タイプ別
      • 有病数:年齢別
  • 東欧
    • ロシア
      • 有病数
      • 有病数:性別
      • 有病数:タイプ別
      • 有病数:年齢別
    • トルコ
      • 有病数
      • 有病数:性別
      • 有病数:タイプ別
      • 有病数:年齢別
  • ラテンアメリカ
    • メキシコ
      • 有病数
      • 有病数:性別
      • 有病数:タイプ別
      • 有病数:年齢別
    • ブラジル
      • 有病数
      • 有病数:性別
      • 有病数:タイプ別
      • 有病数:年齢別
    • アルゼンチン
      • 有病数
      • 有病数:性別
      • 有病数:タイプ別
      • 有病数:年齢別
    • コロンビア
      • 有病数
      • 有病数:性別
      • 有病数:タイプ別
      • 有病数:年齢別

    第7章 寒冷凝集素症(CAD)の治療と管理

    • 治療アルゴリズム
    • 原発性自己免疫性溶血性貧血の診断と管理

    第8章 アンメットニーズ

    第9章 新薬

    • キークロスコンペティション
    • Sutimlimab(BIVV009):Bioverativ Therapeutics
      • 医薬品概要
      • その他の開発動向
      • 臨床開発
      • 安全性と有効性
      • 製品プロファイル
    • APL-2(Pegcetacoplan):Apellis Pharmaceuticals

    第10章 その他の有望な候補薬

    • Bortezomib:Janssen Pharmaceutical
      • 医薬品概要
      • その他の開発動向
      • 臨床開発
      • 安全性と有効性
      • 製品プロファイル
    • Parsaclisib:Incyte Corporation
    • KZR-616:Kezar Life Sciences

    第11章 寒冷凝集素症(CAD):新興10カ国の分析

    • 主な調査結果
    • 新興10カ国の寒冷凝集素症(CAD)の市場規模

    第12章 市場の見通し

    • 新興市場:市場の見通し
    • アジア(台湾・中国)
      • 台湾
        • 寒冷凝集素症(CAD)の総市場規模
        • 寒冷凝集素症(CAD)の市場規模:治療薬別
      • 中国
    • 中東
      • サウジアラビア
      • アラブ首長国連邦
    • 東欧
      • ロシア
      • トルコ
    • ラテンアメリカ
      • メキシコ
      • ブラジル
      • アルゼンチン
      • コロンビア

第13章 市場の成長要因

第14章 市場の障壁

第15章 キーオピニオンリーダーの意見

第16章 付録

  • 調査手法

第17章 DelveInsightのサービス内容

第18章 免責事項

第19章 DelveInsightについて

図表

List of Tables

  • Table 1 : 7MM Cold Agglutinin Disease (CAD) Epidemiology (2017-2030)
  • Table 2 : 7MM Cold Agglutinin Disease (CAD) Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Cold Agglutinin Disease (CAD) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Cold Agglutinin Disease (CAD) Epidemiology in Germany (2017-2030)
  • Table 6 : Cold Agglutinin Disease (CAD) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Cold Agglutinin Disease (CAD) Epidemiology in France (2017-2030)
  • Table 8 : Cold Agglutinin Disease (CAD) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Cold Agglutinin Disease (CAD) Epidemiology in Italy (2017-2030)
  • Table 10 : Cold Agglutinin Disease (CAD) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Cold Agglutinin Disease (CAD) Epidemiology in Spain (2017-2030)
  • Table 12 : Cold Agglutinin Disease (CAD) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Cold Agglutinin Disease (CAD) Epidemiology in the UK (2017-2030)
  • Table 14 : Cold Agglutinin Disease (CAD) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Cold Agglutinin Disease (CAD) Epidemiology in Japan (2017-2030)
  • Table 16 : Cold Agglutinin Disease (CAD) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Cold Agglutinin Disease (CAD) Epidemiology (2017-2030)
  • Figure 2 : 7MM Cold Agglutinin Disease (CAD) Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Cold Agglutinin Disease (CAD) Epidemiology in the United States (2017-2030)
  • Figure 4 : Cold Agglutinin Disease (CAD) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Cold Agglutinin Disease (CAD) Epidemiology in Germany (2017-2030)
  • Figure 6 : Cold Agglutinin Disease (CAD) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Cold Agglutinin Disease (CAD) Epidemiology in France (2017-2030)
  • Figure 8 : Cold Agglutinin Disease (CAD) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Cold Agglutinin Disease (CAD) Epidemiology in Italy (2017-2030)
  • Figure 10 : Cold Agglutinin Disease (CAD) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Cold Agglutinin Disease (CAD) Epidemiology in Spain (2017-2030)
  • Figure 12 : Cold Agglutinin Disease (CAD) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Cold Agglutinin Disease (CAD) Epidemiology in the UK (2017-2030)
  • Figure 14 : Cold Agglutinin Disease (CAD) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Cold Agglutinin Disease (CAD) Epidemiology in Japan (2017-2030)
  • Figure 16 : Cold Agglutinin Disease (CAD) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)
目次
Product Code: DIMI0675

DelveInsight's "Cold Agglutinin Disease (CAD) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Cold Agglutinin Disease (CAD), historical and forecasted epidemiology as well as the Cold Agglutinin Disease (CAD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Cold Agglutinin Disease (CAD) market report provides current treatment practices, emerging drugs, Cold Agglutinin Disease (CAD) market share of the individual therapies, current and forecasted Cold Agglutinin Disease (CAD) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Cold Agglutinin Disease (CAD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Cold Agglutinin Disease (CAD) Disease Understanding and Treatment Algorithm

The DelveInsight Cold Agglutinin Disease (CAD) market report gives a thorough understanding of the Cold Agglutinin Disease (CAD) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Cold Agglutinin Disease (CAD).

Treatment

It covers the details of conventional and current medical therapies available in the Cold Agglutinin Disease (CAD) market for the treatment of the condition. It also provides Cold Agglutinin Disease (CAD) treatment algorithms and guidelines in the United States, Europe, and Japan.

Cold Agglutinin Disease (CAD) Epidemiology

The Cold Agglutinin Disease (CAD) epidemiology division provide insights about historical and current Cold Agglutinin Disease (CAD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Cold Agglutinin Disease (CAD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Cold Agglutinin Disease (CAD) Epidemiology

The epidemiology segment also provides the Cold Agglutinin Disease (CAD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Cold Agglutinin Disease (CAD) Drug Chapters

Drug chapter segment of the Cold Agglutinin Disease (CAD) report encloses the detailed analysis of Cold Agglutinin Disease (CAD) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Cold Agglutinin Disease (CAD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Cold Agglutinin Disease (CAD) treatment.

Cold Agglutinin Disease (CAD) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Cold Agglutinin Disease (CAD) treatment.

Cold Agglutinin Disease (CAD) Market Outlook

The Cold Agglutinin Disease (CAD) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Cold Agglutinin Disease (CAD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Cold Agglutinin Disease (CAD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Cold Agglutinin Disease (CAD) market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Cold Agglutinin Disease (CAD) market in 7MM.

The United States Market Outlook

This section provides the total Cold Agglutinin Disease (CAD) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Cold Agglutinin Disease (CAD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Cold Agglutinin Disease (CAD) market size and market size by therapies in Japan is also mentioned.

Cold Agglutinin Disease (CAD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Cold Agglutinin Disease (CAD) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Cold Agglutinin Disease (CAD) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Cold Agglutinin Disease (CAD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Cold Agglutinin Disease (CAD) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Cold Agglutinin Disease (CAD) emerging therapies.

Reimbursement Scenario in Cold Agglutinin Disease (CAD)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Cold Agglutinin Disease (CAD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Cold Agglutinin Disease (CAD) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Cold Agglutinin Disease (CAD) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Cold Agglutinin Disease (CAD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Cold Agglutinin Disease (CAD) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Cold Agglutinin Disease (CAD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Cold Agglutinin Disease (CAD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Cold Agglutinin Disease (CAD) market

Report Highlights

  • In the coming years, Cold Agglutinin Disease (CAD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Cold Agglutinin Disease (CAD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Cold Agglutinin Disease (CAD). Launch of emerging therapies will significantly impact the Cold Agglutinin Disease (CAD) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Cold Agglutinin Disease (CAD)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Cold Agglutinin Disease (CAD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Cold Agglutinin Disease (CAD) Pipeline Analysis
  • Cold Agglutinin Disease (CAD) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Cold Agglutinin Disease (CAD) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Cold Agglutinin Disease (CAD) Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Cold Agglutinin Disease (CAD) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Cold Agglutinin Disease (CAD) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Cold Agglutinin Disease (CAD) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Cold Agglutinin Disease (CAD) market size during the forecast period (2017-2030)?
  • At what CAGR, the Cold Agglutinin Disease (CAD) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Cold Agglutinin Disease (CAD) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Cold Agglutinin Disease (CAD) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Cold Agglutinin Disease (CAD)?
  • What is the historical Cold Agglutinin Disease (CAD) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Cold Agglutinin Disease (CAD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Cold Agglutinin Disease (CAD)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Cold Agglutinin Disease (CAD) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Cold Agglutinin Disease (CAD) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Cold Agglutinin Disease (CAD) in the USA, Europe, and Japan?
  • What are the Cold Agglutinin Disease (CAD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Cold Agglutinin Disease (CAD)?
  • How many therapies are developed by each company for Cold Agglutinin Disease (CAD) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Cold Agglutinin Disease (CAD) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Cold Agglutinin Disease (CAD) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Cold Agglutinin Disease (CAD) and their status?
  • What are the key designations that have been granted for the emerging therapies for Cold Agglutinin Disease (CAD)?
  • What are the global historical and forecasted market of Cold Agglutinin Disease (CAD)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Cold Agglutinin Disease (CAD) market
  • To understand the future market competition in the Cold Agglutinin Disease (CAD) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Cold Agglutinin Disease (CAD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Cold Agglutinin Disease (CAD) market
  • To understand the future market competition in the Cold Agglutinin Disease (CAD) market

Table of Contents

1. Key Insights

2. Executive Summary of Cold Agglutinin Disease (CAD)

3. Competitive Intelligence Analysis for Cold Agglutinin Disease (CAD)

4. Cold Agglutinin Disease (CAD): Market Overview at a Glance

  • 4.1. Cold Agglutinin Disease (CAD) Total Market Share (%) Distribution in 2017
  • 4.2. Cold Agglutinin Disease (CAD) Total Market Share (%) Distribution in 2030

5. Cold Agglutinin Disease (CAD): Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Cold Agglutinin Disease (CAD) Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Cold Agglutinin Disease (CAD) Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Cold Agglutinin Disease (CAD) Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Cold Agglutinin Disease (CAD) Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Cold Agglutinin Disease (CAD) Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Cold Agglutinin Disease (CAD) Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Cold Agglutinin Disease (CAD) Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Cold Agglutinin Disease (CAD) Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Cold Agglutinin Disease (CAD) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Cold Agglutinin Disease (CAD) Treatment and Management
  • 8.2. Cold Agglutinin Disease (CAD) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Cold Agglutinin Disease (CAD) Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Cold Agglutinin Disease (CAD): Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Cold Agglutinin Disease (CAD) Market Size in 7MM
  • 13.3. Cold Agglutinin Disease (CAD) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Cold Agglutinin Disease (CAD) Total Market Size in the United States
    • 15.1.2. Cold Agglutinin Disease (CAD) Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Cold Agglutinin Disease (CAD) Total Market Size in Germany
    • 15.3.2. Cold Agglutinin Disease (CAD) Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Cold Agglutinin Disease (CAD) Total Market Size in France
    • 15.4.2. Cold Agglutinin Disease (CAD) Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Cold Agglutinin Disease (CAD) Total Market Size in Italy
    • 15.5.2. Cold Agglutinin Disease (CAD) Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Cold Agglutinin Disease (CAD) Total Market Size in Spain
    • 15.6.2. Cold Agglutinin Disease (CAD) Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Cold Agglutinin Disease (CAD) Total Market Size in the United Kingdom
    • 15.7.2. Cold Agglutinin Disease (CAD) Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Cold Agglutinin Disease (CAD) Total Market Size in Japan
    • 15.8.3. Cold Agglutinin Disease (CAD) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Cold Agglutinin Disease (CAD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight